Netizen: Curing Cancer The Parmita Mishra Way

Saturday, March 21, 2026

Curing Cancer The Parmita Mishra Way

Let me show you both paths. What happens today, without this platform

and what I’d actually do if I had one. Assume I had the permits to use my cells, and I could do what I want.

Then you tell me which world you want to live in.
— Parmita Mishra (@parmita) March 21, 2026

2-3 weeks later, your genomic sequencing comes back. An oncologist matches your mutations to a database. A lookup table. They prescribe whatever the standard of care is for patients with your mutation profile.

Not YOUR cancer. Cancers LIKE yours. Based on population averages.
— Parmita Mishra (@parmita) March 21, 2026

Here’s what nobody tells you:

Your cancer has metabolic vulnerabilities, chemical quirks, drug sensitivities that are UNIQUE to your tumor.

no one ever looks for them.

the system doesn’t yet have a way to watch your living cells respond to drugs in real time. only we do.
— Parmita Mishra (@parmita) March 21, 2026

This is also why I think about AI differently than most people do.

Biological foundation models are powerful.

But models without measurement are just elegant speculation.

They need ground truth.
— Parmita Mishra (@parmita) March 21, 2026

Today’s system is incredibly sophisticated.

But in one crucial sense, it is still forensics:

snapshots
inference
delayed feedback

If it were my life, I would want film.

enough yapping. let me show you the other path.
— Parmita Mishra (@parmita) March 21, 2026

I would still sequence everything I could.

Genome. Transcriptome. Mutation landscape. Expression state.

That matters.

But genomics tells you what the code says.
It does not directly tell you what the living system is doing under perturbation.
— Parmita Mishra (@parmita) March 21, 2026

Precigenetics is a microfluidic system with integrated spectroscopy that captures real-time spectral fingerprints of living cells.

No labels or antibodies to order. No killing cells to examine

Lipid content, protein conformation, nucleic acid states, metabolic shifts. Live.
— Parmita Mishra (@parmita) March 21, 2026

Now I screen. Fast.

Not novel compounds

I don’t have 10 years for a de novo drug program.

So I go with: Drug repurposing. This is not our focus internally today but who cares, I will die if I stop.

Now I flow them across my cells and I WATCH.
— Parmita Mishra (@parmita) March 21, 2026

MBOP takes combinations for screening.

I run combinations. Drug A alone, Drug B alone, A+B together.

I watch synergy or antagonism unfold in the spectra in real time.

No waiting 2 weeks for a sequencing report. Empirical, observation-native pharmacology on MY cells. In days.
— Parmita Mishra (@parmita) March 21, 2026

That means some off-label drug nobody would ever think to try based on my genomic profile - a statin, a metformin analog, an old antifungal - might be hammering my cells’ metabolism in exactly the right way.
— Parmita Mishra (@parmita) March 21, 2026

This is the loop I care about most:

models generating hypotheses
live measurement testing them
measurement improving the models
models making the next screen smarter

That is not a feature.

It is a new operating system for biology.
— Parmita Mishra (@parmita) March 21, 2026

It cost us millions. Millions to develop our hardware. Our infrastructure. Our team worked endlessly.

But here’s the funny part.

Now that we already have all of this, how much would it cost extra to save my own life?
— Parmita Mishra (@parmita) March 21, 2026

A single round of targeted therapy that might not even work costs $10,000-$30,000/month.

A failed first-line treatment doesn’t just cost money. It costs months of your life.

And the data flywheel eventually makes even this cost nonexistent. It’ll all go in silico.
— Parmita Mishra (@parmita) March 21, 2026

Tomorrow, with the rest of the work we do on resistance, on toxicity, on targets,

We would be able to generate a completely new compound, one day, entirely using AI and that one biopsy tissue.

And the safety profile? The accuracy? It would only climb up.

Today it’s 97%…
— Parmita Mishra (@parmita) March 21, 2026

I built this because I watched someone I love die in a system that could not see fast enough.

My aunt had ALS. And she didn’t have this.

She didn’t know what disease she had at all.

She lost the ability to speak, to breathe, helpless.
— Parmita Mishra (@parmita) March 21, 2026

Today, I realized something incredible.

If my own life were on the line, I, a biologist, know what I am building could actually save me.

I am so grateful to be someone who can say that.

I already know what I would want.

I would want to watch.

That is exactly what I built.
— Parmita Mishra (@parmita) March 21, 2026

This is revolutionary. What I don't understand is why have you not raised gobbles of money already.
— Paramendra Kumar Bhagat (@paramendra) March 21, 2026

@PeterKolchinsky @LifeSciVC @rtnarch @DavidASteinberg @bmgallagherjr @ohadhammer @kulesatony @paras_biotech @ameekapadia @AndyBiotech 👆
— Paramendra Kumar Bhagat (@paramendra) March 21, 2026